Horizon Therapeutics Public Limited Company (HZNP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Horizon Therapeutics Public Limited Company (HZNP) trades at $116.30 with AI Score 54/100 (Grade B). Horizon Therapeutics Public Limited Company is a biotechnology firm focused on rare, autoimmune, and severe inflammatory diseases. Market cap: $26.6B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for HZNP: HZNP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HZNP against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HZNP: 1/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Horizon Therapeutics Public Limited Company (HZNP) Healthcare & Pipeline Overview
Horizon Therapeutics, an Ireland-based biotechnology company, discovers, develops, and commercializes medicines for rare, autoimmune, and severe inflammatory diseases. With a portfolio of 12 medicines, Horizon operates in the Orphan and Inflammation segments, addressing critical needs in niche therapeutic areas and demonstrating a commitment to specialized healthcare solutions.
What Is the Investment Thesis for HZNP?
Horizon Therapeutics presents a compelling investment case based on its focus on rare and inflammatory diseases, which often command premium pricing and offer market exclusivity. With a P/E ratio of 51.1 and a profit margin of 14.4%, the company demonstrates solid profitability. Key value drivers include the continued growth of TEPEZZA, a treatment for thyroid eye disease, and KRYSTEXXA, for uncontrolled gout. Upcoming catalysts include potential label expansions for existing products and advancements in its pipeline. However, investors may want to evaluate potential risks such as competition from biosimilars and changes in healthcare regulations. The company's beta of 1.01 indicates market-average volatility.
Based on FMP financials and quantitative analysis
HZNP Key Highlights
- Market capitalization of $26.6B reflects investor confidence in Horizon's growth prospects and market position.
- Profit margin of 14.4% indicates efficient operations and strong pricing power in its niche markets.
- Gross margin of 74.6% highlights the high value of its pharmaceutical products.
- Portfolio of 12 medicines diversified across rare diseases, gout, ophthalmology, and inflammation provides revenue stability.
- Strategic collaborations with companies like Halozyme Therapeutics and Arrowhead Pharmaceuticals enhance its R&D capabilities.
Who Are HZNP's Competitors?
HZNP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABMD Abiomed, Inc. | $381.02 | +0.00% | $17.2B | 60 |
| BDX Becton, Dickinson and Company | $154.48 | -2.33% | $56.0B | 73 |
| COR Cencora, Inc. | $303.99 | -1.27% | $59.1B | 77 |
| CTLT Catalent, Inc. | $63.48 | +0.00% | $11.5B | 48 |
| DNA Ginkgo Bioworks Holdings, Inc. | $7.55 | -4.55% | $493M | — |
| ALPMF Astellas Pharma Inc. | $14.50 | +6.03% | $26.0B | 58 |
| BIIB Biogen Inc. | $199.95 | -2.93% | $29.5B | 78 |
| ALPMY Astellas Pharma Inc. | $13.30 | +0.15% | $23.8B | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HZNP's Key Strengths?
- Strong portfolio of marketed products in niche therapeutic areas.
- Focus on rare diseases provides pricing power and market exclusivity.
- Experienced management team with a track record of successful product launches.
- Strategic collaborations enhance R&D capabilities.
What Are HZNP's Weaknesses?
- Reliance on a limited number of key products.
- Potential for competition from biosimilars and generic drugs.
- Exposure to regulatory risks and changes in healthcare policies.
- High R&D expenses.
What Could Drive HZNP Stock Higher?
- Continued growth in sales of TEPEZZA for thyroid eye disease.
- Expansion of KRYSTEXXA use in combination with immunomodulatory therapies.
- Potential regulatory approvals for new pipeline products.
- Strategic acquisitions and collaborations to expand the portfolio.
- Geographic expansion into new markets.
What Are the Key Risks for HZNP?
- Rich valuation — a P/E of 51.1 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Insider selling — insiders were net sellers of roughly $6.9M recently.
- Competition from biosimilars and generic drugs.
- Unfavorable changes in healthcare reimbursement policies.
- Product liability claims and litigation.
- Failure to obtain regulatory approvals for new products.
- Reliance on key products, making the company vulnerable to market changes.
What Are the Growth Opportunities for HZNP?
- Growth opportunity 1: Expanding the label for TEPEZZA, its treatment for thyroid eye disease, represents a significant growth opportunity. Thyroid eye disease affects a substantial patient population, and TEPEZZA has demonstrated strong efficacy in clinical trials. Further label expansions to include earlier stages of the disease or additional indications could significantly increase its market reach. The market for thyroid eye disease treatments is projected to grow, driven by increased diagnosis rates and a growing awareness of available therapies. This expansion could unfold over the next 2-3 years.
- Growth opportunity 2: KRYSTEXXA, Horizon's treatment for uncontrolled gout, has the potential for further growth through increased adoption and expansion into new patient populations. Gout is a prevalent condition, and KRYSTEXXA offers a unique mechanism of action for patients who have failed other therapies. Horizon can drive growth by educating physicians and patients about the benefits of KRYSTEXXA and expanding its use in combination with other treatments. The gout treatment market is expected to expand, driven by an aging population and increasing prevalence of risk factors. This growth is expected over the next 3-5 years.
- Growth opportunity 3: Horizon's pipeline of novel drug candidates represents a key growth opportunity. The company is investing in research and development to discover and develop new treatments for rare diseases and inflammatory conditions. Advancing these candidates through clinical trials and obtaining regulatory approvals could lead to the launch of new products and expansion of its revenue streams. The timeline for this growth depends on the success of clinical trials and regulatory review processes, but new product launches could occur within the next 5-7 years.
- Growth opportunity 4: Strategic acquisitions and collaborations can provide Horizon with access to new technologies, products, and markets. The company has a history of acquiring companies and partnering with other firms to expand its portfolio and capabilities. Pursuing additional acquisitions and collaborations could accelerate its growth and diversification. The timing and impact of these opportunities are difficult to predict, but they could significantly enhance Horizon's long-term growth prospects.
- Growth opportunity 5: Geographic expansion into new markets represents another growth opportunity for Horizon. The company currently has a significant presence in the United States and Europe but could expand its operations into other regions, such as Asia and Latin America. Entering new markets would allow it to reach a larger patient population and increase its revenue base. The timeline for this expansion depends on regulatory approvals and market access considerations, but it could occur over the next 3-5 years.
What Opportunities Does HZNP Have?
- Expanding the label for existing products to new indications.
- Acquiring new products and technologies to diversify its portfolio.
- Entering new geographic markets to reach a larger patient population.
- Developing novel therapies for rare diseases with unmet needs.
What Threats Does HZNP Face?
- Increased competition from other pharmaceutical companies.
- Unfavorable changes in healthcare reimbursement policies.
- Product liability claims and litigation.
- Failure to obtain regulatory approvals for new products.
What Are HZNP's Competitive Advantages?
- Patent protection for its proprietary pharmaceutical products.
- Orphan drug designation provides market exclusivity for certain treatments.
- Specialized expertise in rare diseases and inflammation.
- Established relationships with healthcare providers and patient advocacy groups.
What Does HZNP Do?
Founded in 2005, Horizon Therapeutics Public Limited Company has evolved into a prominent biotechnology company focused on addressing critical unmet needs in rare, autoimmune, and severe inflammatory diseases. Originally known as Horizon Pharma Public Limited Company, the company rebranded in May 2019 to reflect its expanding focus on therapeutics. Headquartered in Dublin, Ireland, Horizon operates with a global footprint, including significant operations in the United States and Germany. The company's portfolio comprises 12 marketed medicines, segmented into Orphan and Inflammation categories. Key products include TEPEZZA for thyroid eye disease, KRYSTEXXA for uncontrolled gout, RAVICTI for urea cycle disorders, and UPLIZNA for neuromyelitis optica spectrum disorder. These medicines target niche markets with high unmet needs, providing Horizon with a degree of market exclusivity and pricing power. Horizon's strategy involves a combination of internal research and development, strategic acquisitions, and collaborations to expand its pipeline and commercial reach. The company has established partnerships with firms like HemoShear Therapeutics, Alpine Immune Sciences, Halozyme Therapeutics, and Arrowhead Pharmaceuticals to advance its research efforts and explore new therapeutic modalities. Horizon's commitment to innovation and patient-centricity has positioned it as a key player in the rare disease and inflammation space.
What Products and Services Does HZNP Offer?
- Discovers and develops medicines for rare diseases.
- Commercializes treatments for autoimmune conditions.
- Offers therapies for severe inflammatory diseases.
- Markets TEPEZZA for thyroid eye disease.
- Provides KRYSTEXXA for uncontrolled gout.
- Develops treatments for urea cycle disorders.
- Offers solutions for neuromyelitis optica spectrum disorder.
How Does HZNP Make Money?
- Develops and commercializes proprietary pharmaceutical products.
- Focuses on niche markets with high unmet medical needs.
- Utilizes a combination of internal R&D and strategic acquisitions.
- Generates revenue through product sales and licensing agreements.
What Industry Does HZNP Operate In?
Horizon Therapeutics operates within the pharmaceutical industry, specifically focusing on rare diseases and inflammation. The market for rare disease treatments is growing due to increased awareness, improved diagnostics, and regulatory incentives such as orphan drug designation. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms specializing in niche therapeutic areas. Horizon differentiates itself through its focus on specific rare diseases and its established portfolio of marketed products.
Who Are HZNP's Key Customers?
- Patients with rare diseases.
- Individuals with autoimmune conditions.
- People suffering from severe inflammatory diseases.
- Healthcare providers prescribing Horizon's medications.
Company Profile
Horizon Therapeutics Public Limited Company operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Timothy P. Walbert. HZNP has traded publicly since 2011.
F-Score 8/9Financial Health
Horizon Therapeutics Public Limited Company's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.08 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 11%Key Financial Metrics
Return on equity for Horizon Therapeutics Public Limited Company stands at 10.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.7%, showing how much profit it generates from its asset base. HZNP trades at a trailing price-to-earnings ratio of 51.10, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.0%, the inverse of the P/E and a quick read on earnings relative to price.
HZNP Valuation & Market Position
With a $26.6B market cap, Horizon Therapeutics Public Limited Company sits in the large-cap segment of the market. Relative to its peer group, HZNP's quantitative score of 54/100 is below the peer average of 65/100.
Net sellingInsider Activity
The most recent 12 insider filings for Horizon Therapeutics Public Limited Company break down as 12 sales and 0 purchases. On net that is roughly 210K shares disposed (about $6.9M), a signal worth weighing alongside the fundamentals.
HZNP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Strong portfolio of marketed products in niche therapeutic areas.
- Focus on rare diseases provides pricing power and market exclusivity.
- Experienced management team with a track record of successful product launches.
- Strategic collaborations enhance R&D capabilities.
Bear Case
- Reliance on a limited number of key products.
- Potential for competition from biosimilars and generic drugs.
- Exposure to regulatory risks and changes in healthcare policies.
- High R&D expenses.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HZNP Latest News
No recent news available for HZNP.
HZNP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HZNP.
Price Targets
Wall Street price target analysis for HZNP.
HZNP MoonshotScore
What does this score mean?
The MoonshotScore rates HZNP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Timothy P. Walbert
Chairman, President and Chief Executive Officer
Timothy P. Walbert has served as the Chairman, President, and Chief Executive Officer of Horizon Therapeutics since 2010. Prior to joining Horizon, he held leadership positions at IDM Pharma, including president, chief executive officer, and director. He also served as executive vice president, commercial operations at NeoPharm, Inc., and spent 14 years at Abbott, where he held various positions in sales, marketing, and general management. Walbert holds a BA in marketing from Arizona State University.
Track Record: Under Timothy Walbert's leadership, Horizon Therapeutics has transformed from a small pharmaceutical company into a leading biotechnology firm focused on rare diseases. He has overseen the successful launch and commercialization of several key products, including TEPEZZA and KRYSTEXXA, and has led the company through multiple strategic acquisitions and partnerships. Walbert has also been instrumental in building a strong corporate culture and fostering innovation within the organization.
Common Questions About HZNP (Healthcare)
What does the AI Score mean for HZNP?
HZNP holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Horizon Therapeutics Public Limited Company is a biotechnology firm focused on rare, autoimmune, and severe inflammatory diseases. Their portfolio includes 12 medicines across rare diseases, gout …
What does Horizon Therapeutics Public Limited Company do?
Horizon Therapeutics is a biotechnology company focused on discovering, developing, and commercializing medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation, and its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.
What do analysts say about HZNP stock?
Analyst consensus on Horizon Therapeutics stock is generally positive, reflecting the company's strong growth prospects and market position in the rare disease and inflammation space. Key valuation metrics, such as the P/E ratio of 51.1, suggest that the stock is trading at a premium compared to some of its peers.
What are the main risks for HZNP?
The main risks for Horizon Therapeutics include competition from biosimilars and generic drugs, which could erode the company's market share and pricing power. Unfavorable changes in healthcare reimbursement policies could also negatively impact its revenue and profitability. Product liability claims and litigation represent another potential risk, particularly given the nature of the company's pharmaceutical products.
What are the key factors to evaluate for HZNP?
Horizon Therapeutics Public Limited Company (HZNP) holds an AI score of 54/100 (moderate). P/E: 51.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does HZNP data refresh on this page?
HZNP's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HZNP's recent stock price performance?
Horizon Therapeutics Public Limited Company (HZNP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong portfolio of marketed products in niche therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HZNP overvalued or undervalued right now?
Horizon Therapeutics Public Limited Company (HZNP) trades at 51.1x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HZNP before investing?
Before investing in Horizon Therapeutics Public Limited Company (HZNP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources.
- AI analysis is pending and may provide additional insights.